Sinotau Receives FDA NDA Approval for MK‑6240 Tau PET Imaging Agent
Beijing Sinotau International Pharmaceutical Technology Co., Ltd. announced today that the New Drug Application (NDA) for...
Drug
UCB Wins FDA Approval for KYGEVVI in Rare Mitochondrial Disease TK2d
UCB (EBR: UCB) announced that KYGEVVI received FDA approval for the treatment of adult and...
Dizal Highlights Breakthrough Findings for golidocitinib and birelentinib at ASH 2025
Dizal Pharmaceutical Co., Ltd. (SHA: 688192) announced that multiple research updates for its two core...
Jiangsu Vcare’s VC004 Joins NMPA’s SPARK Oncology Program
The Center for Drug Evaluation (CDE) under the National Medical Products Administration (NMPA) has officially...
Jiangsu Hengrui Secures Priority Review for HRS‑5965 in China’s Rare‑Disease Portfolio
Jiangsu Hengrui Pharmaceuticals (SHA: 600276, HKG: 1276) announced that the National Medical Products Administration (NMPA)...
Pluvicto Radioligand Therapy Receives Dual NMPA Approvals in China
Novartis (NYSE: NVS) has announced that its Lutetium‑177‑labelled therapy Pluvicto (lutetium ¹⁷⁷Lu‑vipivotide tetraxetan) now holds...
Sichuan Biokin Secures Breakthrough Therapy Designation for HER2‑Targeted ADC T‑Bren
China’s Sichuan Biokin Pharmaceutical Co., Ltd. (SHA: 688506) announced that its proprietary antibody‑drug conjugate (ADC)...
Shenzhen Kangtai Biological Products Launches Phase I Trial for Infant Influenza Vaccine
China‑based Shenzhen Kangtai Biological Products Co., Ltd. (SHE: 300601) has entered the clinical stage with...
MSD Secures Full Global Rights to MK‑8690 After $150 Million Settlement with Falk Pharma
Merck Sharp & Dohme Inc. (MSD, NYSE: MRK), through its 2023 acquisition of Prometheus BioSciences,...
Zhejiang Acea Pharma Secures Conditional NMPA Approval for Olgotrelvir Sodium Capsules – First Dual‑Target COVID‑19 Oral Antiviral in China
Zhejiang Acea Pharmaceutical Co., Ltd. announced that China’s National Medical Products Administration (NMPA) has granted...
Daiichi Sankyo’s Enhertu Wins CDE Acceptance for First‑Line HER2‑Positive Breast‑Cancer Indication in China
Daiichi Sankyo Co., Ltd. (TYO: 4568) announced that China’s Center for Drug Evaluation (CDE) of...
Eli Lilly Announces Phase 3 ATTAIN‑PAD Trial for Oral GLP‑1 Agent orforglipron
Eli Lilly (NYSE: LLY), a global biopharma titan, will commence the ATTAIN‑PAD phase 3 study—an ambitious,...
CARsgen Therapeutics Shares Promising Early Results for Allogeneic CAR‑T Products
China‑based CARsgen Therapeutics Holdings Limited (HKG: 2171) unveiled clinical data for two allogeneic CAR‑T candidates...
Hengrui Gets NMPA Green Light for Rezvilutamide‑HS‑20093 Combination Trial in Prostate Cancer
China‑based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276, HKG: 1276) announced today that the China...
CStone Receives NMPA Approval for CS2009 Phase II Trial in Advanced Solid Tumors
China‑based CStone Pharmaceuticals (HKG: 2616), announced today that the China National Medical Products Administration (NMPA)...
GenAns Biotechnology Receives FDA Fast‑Track Designation for GA001 Injection, a Promising Gene‑Therapy for Retinitis Pigmentosa
China‑based GenAns Biotechnology Co., Ltd. announced that its proprietary gene‑therapy drug GA001 injection received Fast‑Track...
Ascentage Pharma Unveils Promising Results for Olverembatinib and Lisaftoclax at the 67th ASH Annual Meeting
China‑based Ascentage Pharma (HKG: 6855) showcased data from its two flagship pipelines—olverembatinib (HQP1351), a first‑in‑China...
Shanghai CirCode’s HM2002 Gains China NMPA Approval for Refractory Angina
Shanghai CirCode Biomed Co. Ltd. announced that its self‑developed circular RNA (circRNA) therapeutic HM2002 has received...
TransThera Sciences and Neurocrine Biosciences Ink $881.5 M NLRP3 Collaboration
TransThera Sciences (Nanjing) Inc. (HKG: 2617) announced today that it has entered into a royalty‑bearing patent‑assignment...
Simnova’s DLL3‑Targeted CAR‑T (SNC115) Wins First‑In‑China Clinical‑Trial Approval for Relapsed SCLC
Shanghai Simnova Biotech Co., Ltd. announced that its self‑developed anti‑DLL3 chimeric antigen receptor T‑cell (CAR‑T)...